GlassScriptPhysician profile
Hung-Jie Jeng
NPI 1518367887
$3,305.95
in general payments reported to CMS, 2019-2025
25 companies · $703 in 2025
The $703 reported for 2025 was more than what 79% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $651 · 2022: $545 · 2023: $652 · 2024: $755 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,127.55 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $452.82 | 2022-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $180.93 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $150.26 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.33 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $138.76 | 2021-2023 | Mounjaro |
| Sumitomo Pharma America, INC. | $124.77 | 2023 | Gemtesa |
| Esperion Therapeutics, INC. | $124.36 | 2021 | |
| Abbvie INC. | $115.09 | 2023-2025 | |
| Abbott Laboratories | $110.97 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $109.84 | 2021-2024 | Rybelsus, Ozempic |
| Almatica Pharma LLC | $99.45 | 2023-2024 | Loreev Xr |
| Novartis Pharmaceuticals Corporation | $95.94 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $62.18 | 2022 | |
| Dexcom, INC. | $36.90 | 2022-2023 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.64 | 2024-2025 | |
| Gilead Sciences, INC. | $32.49 | 2023 | |
| Merck Sharp & Dohme LLC | $32.06 | 2021 | |
| Glaxosmithkline, LLC. | $31.07 | 2023 | Shingrix, Arexvy |
| Vivus LLC | $22.24 | 2022 | |
| Eisai INC. | $21.20 | 2021 | |
| Redhill Biopharma INC. | $19.14 | 2021 | |
| Radius Health, INC. | $17.83 | 2023 | Tymlos |
| Horizon Therapeutics Plc | $15.85 | 2022 | |
| Genentech USA, INC. | $9.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung-Jie Jeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.